Lifestyle Asset Management Inc. Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Lifestyle Asset Management Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 2,472 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.

A number of other hedge funds have also added to or reduced their stakes in GILD. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $25,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the 2nd quarter worth $33,000. Finally, Friedenthal Financial bought a new stake in shares of Gilead Sciences in the third quarter valued at about $50,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Piper Sandler boosted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Oppenheimer increased their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, UBS Group raised their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Trading Down 0.1 %

Shares of NASDAQ:GILD opened at $92.92 on Friday. The business has a 50-day moving average price of $91.63 and a 200-day moving average price of $84.63. The stock has a market cap of $115.80 billion, a price-to-earnings ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the business posted $2.29 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. Gilead Sciences’s payout ratio is currently 3,422.22%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 over the last quarter. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.